To compare the rate and extent of absorption of Abrika Bupropion 150 mg XL Tablet to that of Wellbutrin XL® 150 mg Tablet after a single, one-tablet dose in fasted subjects.
Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design. Official Title: A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion XL Tablets Formulation in Fasted, Normal, Healthy Subjects. Further study details as provided by Actavis Elizabeth LLC: Primary Outcome Measures: Rate and Extend of Absorption
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
28
A: Experimental Subjects received Abrika formulated products under fasting conditions
B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
SFBC Ft. Myers, Inc.
Fort Myers, Florida, United States
Rate and Extend of Absorption
Time frame: 96 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.